Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 39

NHS England released this framework in late 2017. This document supports NHS commissioners to act promptly to make the most of the opportunity presented by increased competition among biological medicines, including biosimilars. In particular, this framework sets out the importance of taking a collaborative approach to the commissioning of innovator biologics and biosimilars.⁶⁷ A companion commentary on preparing for the biologic switch is also available.⁶⁸